Hemostasis and Thrombosis Center

The Hemostasis and Thrombosis Center (HTC) at Children’s Hospital Los Angeles was established in 1976, becoming one of the first Hemophilia Treatment Centers in the country. With over 1,000 patients, we are one of the biggest coagulation centers in both the United States and the world. Serving as an international referral center for children with bleeding and clotting disorders, our HTC provides excellent clinical care and research.

Through collaboration, we provide one of the most diverse clinical trial programs for patients with hemophilia and thrombosis by offering the latest treatment options to our patients before they are commercially available. For the past eight years, we have also had a robust and thriving 340B Program. Read more about the 340B Program in the section below. This program allows CHLA to offer hemophilia patients a range of services, such as educational events, support groups, and clinical trials.

About the Hemostasis and Thrombosis Center

Our clinical staff members are all experts in bleeding and clotting disorders, providing the most up-to-date treatments available to our patients. Patients from all over the country are referred to us for our studies and procedures. We are one of just a few sites in the United States that is conducting gene therapy research in patients with hemophilia. In addition, we are also one of a limited number of locations that is providing a procedure called radioisotopic synovectomy, which is a medical procedure whereby a radionuclide is injected into a joint in order to treat inflammatory changes that have resulted as a result of an underlying disease process, to our patients with hemophilia and severe joint disease. The HTC also has one of the largest inhibitor patient populations in the world.

  • Commonly Treated Disorders
  • Comprehensive Care
  • Clinical Trials and Research
  • Hemophilia Treatment Center
  • Advanced Fellowship Training
  • 340B Program
  • Hemophilia Fun Day

Bleeding Disorders

  • Hemophilia A and B
  • von Willebrand disease
  • Rare factor deficiencies
  • Platelet function disorders

Clotting Disorders

  • Venous thrombosis
  • Arterial thrombosis
  • Stroke
  • Thrombophilia

Our team offers patients comprehensive care by collaborating with a multidisciplinary team of experts. We want to care for the physical, mental, and emotional needs of our patients and their families. Once the patient is assessed, we work together to create a patient-centered treatment plan.

Our patients are evaluated and cared for by a team of experts:

  • Hematologist - doctor who specializes in blood
  • Nurse Practitioner
  • Physical Therapist
  • Clinical Neuropsychologist
  • Social Worker
  • Orthopedist - doctor who specializes in bones, joints, and muscles
  • Other specialists available by referral

We also offer three multidisciplinary clinics for patients who may benefit from a specialist consult. 

  • Adolescent-Hematology Clinic: held in partnership with Adolescent Medicine, this clinic is for teenagers with bleeding or clotting problems, such as heavy periods or need for contraception after having a blood clot. 
  • Hematology-Orthopedics Clinic: held in partnership with the Orthopedic Center, this clinic is for patients with bleeding problems like hemophilia who also have chronic issues with their joints.
  • Stroke Clinic: held in partnership with Neurology, this clinic is for patients with complications from a blood clot in the brain (stroke).

The Hemostasis and Thrombosis Center has been at the center of hemophilia research since the 1980s. We have taken part in many studies and clinical trials that have set the standard for current treatment. Our priority is making sure that patients have the latest, most effective, and safest treatment. The Center is involved in cutting-edge research of new treatments for bleeding and clotting disorders and focusing on creating new ways to analyze how well treatments work.

Click here to see our open clinical trials.

Hemophilia is a complicated condition. Doctors and nurses who have a vast amount of knowledge and expertise in hemophilia are able to help prevent some serious complications. By taking your child to a Hemophilia Treatment Center, your child will be given excellent medical care by providers who are experts in their field.

The Hemophilia Treatment Center (HTC) in the Cancer and Blood Disease Institute at Children’s Hospital Los Angeles was one of the first federally-designated HTCs in the United States. Since 1976, it has remained the largest HTC in California. It is one of four HTCs in the Los Angeles metropolitan area and the only pediatric HTC in Los Angeles.

The Pediatric Hemostasis and Thrombosis Fellowship at Children’s Hospital Los Angeles is designed to provide an additional 1-2 years of training specific to pediatric coagulation disorders following completion of a pediatric hematology/oncology fellowship. The objective of the fellowship is to provide advanced training in the diagnosis and treatment of children and young adults with bleeding and thrombotic disorders, which includes hemophilia, von Willebrand disease, platelet function disorders, rare factor deficiencies, and venous and arterial thrombosis. In addition, the fellow is able to participate in an extensive clinical research program and will be given the opportunity to conduct their own research study.

As one of the largest pediatric hemostasis and thrombosis treatment centers in the world, the HTC is a recognized international leader in patient care, clinical research, and education. It has both the clinical and laboratory resources to provide an in-depth training in coagulation.

Please click here to find out more information about our advanced training program.

What is the 340B Pharmacy Program?

  • The 340B Pharmacy Program allows HTCs to buy clotting factor at a discounted rate from manufacturers and deliver it to their patients. The income made from the program is used to provide and expand services to all of our patients.
  • CHLA’s 340B Pharmacy Program is called the CHLA Hemophilia Outpatient Made Easy (HOME) Program.
  •  Our HOME Program works just like other home care pharmacies and offers:
    • Home or office delivery of factor, supplies and other medicines
    • A dedicated patient care coordinator
    • Clotting factor authorizations
    • In-home nursing/infusion
    • Education
    • Pharmacy staff on-call 24/7

What patient services does the HOME Program fund?

Thanks to funding from the HOME Program, we’re able to offer all our patients the following services:

Clinical Services

  • Comprehensive clinic visits with our multidisciplinary team (Learn more about clinic visits in the above Comprehensive Care section)
  • Specialty clinics, such as orthopedics and adolescent medicine
  • Consultations with patient’s other care providers, such as primary care physicians
  • Hematologist on-call 24/7

Educational and Support Services

  • Insurance/financial counseling
  • Guided transition of care for teens with bleeding disorders
  • Educational events
  • Support groups

Psychological Services

  • Neuropsychological/psychological consults and evaluations

School and Career Services

  • School consultation and advocacy
    • Help with 504 plans and individualized education plans (IEPs)
    • Communication with college Students With Disabilities offices
  •  Presentations for staff and students
  • Scholarship resources

You have a choice.

Enrollment in the HOME Program is voluntary. If your insurance allows, you may choose CHLA HOME as your factor provider. You may also choose another home care company for your factor needs. All CHLA patients receive the same quality of care regardless of which factor provider they use.

CHLA respects and supports your right to choose your own home care pharmacy. We will gladly give you tools to help you make an informed choice. Feel free to contact us with any questions or to learn more about choosing a factor provider.

Children’s Hospital Los Angeles hosts an annual hemophilia conference for kids and adults living with hemophilia and their loved ones. For more information, please click here.